Literature DB >> 2452749

Desensitization of platelets to iloprost. Loss of specific binding sites and heterologous desensitization of adenylate cyclase.

K Jaschonek1, C Faul, H Schmidt, W Renn.   

Abstract

The binding characteristics of [3H]prostacyclin and [3H]iloprost ([3H]5-[(E)-(1S,5S,6R,7R)-7-hydroxy-6-[(E)-(3S,4RS) -3-hydroxy-4-methyl-1-octen-6-inyl]-bicyclo[3.3.0]octan-3-yl idene] -pentanoic acid) and platelet adenylate cyclase activities were investigated in platelet-rich plasma preincubated with iloprost. The exposure of platelets to 0.1 microM iloprost (12 h, 20 degrees C) caused a significant loss of iloprost binding sites (P less than 0.01) without causing changes in binding affinity. This loss of specific [3H]iloprost binding was time- and dose-dependent. The reduction of iloprost receptor density was accompanied by an impaired responsiveness of platelet adenylate cyclase to iloprost, prostaglandin D2 and forskolin. In contrast, basal adenylate cyclase activity was not affected by iloprost pretreatment. The diminished response of the enzyme to GTP and NaF pointed to an involvement of the stimulatory guanyl nucleotide-binding protein (Gs) in iloprost-induced heterologous desensitization. Consequently, [32P]NAD+ and cholera toxin were used for the direct labelling of Gs. Platelet membranes desensitized to iloprost incorporated less label into the 45 kD subunit of Gs. These data suggest that the site of action of iloprost for heterologous desensitization of human platelet adenylate cyclase is located on Gs.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2452749     DOI: 10.1016/0014-2999(88)90777-7

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  12 in total

1.  Internalization and down-regulation of the prostacyclin receptor in human platelets.

Authors:  S Giovanazzi; M R Accomazzo; O Letari; D Oliva; S Nicosia
Journal:  Biochem J       Date:  1997-07-01       Impact factor: 3.857

2.  Regulation of prostacyclin and prostaglandin E(2) receptor mediated responses in adult rat dorsal root ganglion cells, in vitro.

Authors:  D K Rowlands; C Kao; H Wise
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

Review 3.  Prostacyclin receptor regulation--from transcription to trafficking.

Authors:  C Midgett; J Stitham; K A Martin; J Hwa
Journal:  Curr Mol Med       Date:  2011-10       Impact factor: 2.222

4.  Segregation of discrete GS alpha-mediated responses that accompany homologous or heterologous desensitization in two related somatic hybrids.

Authors:  E Kelly; M Keen; P Nobbs; J MacDermot
Journal:  Br J Pharmacol       Date:  1990-02       Impact factor: 8.739

5.  Prostacyclin-dependent cyclic AMP formation in endothelial cells.

Authors:  H Schröder; K Schrör
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-01       Impact factor: 3.000

6.  Increased Gsα within blood cell membrane lipid microdomains in some depressive disorders: an exploratory study.

Authors:  John J Mooney; Jacqueline A Samson; Nancy L McHale; Kathleen M Pappalarado; Jonathan E Alpert; Joseph J Schildkraut
Journal:  J Psychiatr Res       Date:  2013-03-13       Impact factor: 4.791

7.  Iloprost antagonizes the increase in internal calcium concentration induced by alpha-thrombin in human platelets: a study of desensitization.

Authors:  E Cecchi; L Capone; C Ruocco; A Fazzini; A Mugelli; A Giotti; P Failli
Journal:  Cardiovasc Drugs Ther       Date:  1995-12       Impact factor: 3.727

Review 8.  Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures.

Authors:  S M Grant; K L Goa
Journal:  Drugs       Date:  1992-06       Impact factor: 9.546

9.  Effects of the prostanoids on the proliferation or hypertrophy of cultured murine aortic smooth muscle cells.

Authors:  Takayuki Fujino; Koh-ichi Yuhki; Takehiro Yamada; Akiyoshi Hara; Osamu Takahata; Yuji Okada; Chun-Yang Xiao; Hong Ma; Hideji Karibe; Yasunori Iwashima; Jun Fukuzawa; Naoyuki Hasebe; Kenjiro Kikuchi; Shuh Narumiya; Fumitaka Ushikubi
Journal:  Br J Pharmacol       Date:  2002-06       Impact factor: 8.739

10.  Acute reduction of TxA2 platelet binding sites after in vivo administration of a TxA2 receptor inhibitor.

Authors:  P A Modesti; A Colella; I Cecioni; G F Gensini; R Abbate; G G Neri Serneri
Journal:  Br J Clin Pharmacol       Date:  1991-04       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.